Pandey A, Okaj I, Kaur H, et al. - The incidence or recurrence of atrial fibrillation/flutter (AF) could be reduced with sodium-glucose co-transporter (SGLT) inhibitors.

• An analysis of randomized controlled trials comparing an SGLT inhibitor to placebo or no therapy for the rate of AF reported as an adverse event (primary outcome) and a composite of hospitalization/urgent visit for heart failure (HF) or cardiovascular death, stratified by history of AF at baseline (secondary outcome).

• A total of 30 eligible trials (71,553 participants) reported on AF events, and three trials documented secondary outcome (18,826 participants).

• According to moderate quality evidence, SGLT inhibitors are associated with a lower risk of AF events (1.0% vs 1.4%; risk ratio 0.78).

• Patients with AF as well as those without AF exhibited a reduction in a composite of HF hospitalization or cardiovascular death when they were treated with SGLT inhibitors.